Diagnostics News and Research

RSS

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults.

From Quest Diagnostics 18 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

USPTO issues notice of allowance to Vermillion's Peripheral Artery Disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Panel of Biomarkers for Peripheral Artery Disease" to the company.

18 May 2011

Celgene, Foundation Medicine partner for clinical cancer genomic testing platforms

Foundation Medicine, Inc., a personalized cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine clinical care, today announced a strategic collaboration with Celgene Corporation.

17 May 2011

Boston Software Systems to sponsor Revenue Cycle track of presentations at 2011 MUSE Conference

Boston Software Systems, the leader in workflow automation technology to the healthcare market, today announced that it is participating in the 2011 MUSE International Conference in Nashville, May 31-June 3 and will be sponsoring the Revenue Cycle track of presentations.

16 May 2011

GenturaDx completes external HSV 1&2 alpha studies for IDbox System

Molecular diagnostics company GenturaDx announces the completion of external HSV 1&2 alpha studies for its IDbox instrument and cassette-based tests. Conducted at an external CLIA laboratory, the study analyzed more than 130 samples, including more than 70 clinical specimens.

16 May 2011

Simple, minimal invasive technique could help detect early-stage lung cancer

A simple, minimally-invasive technique using cells from the interior of the nose could help clinicians detect lung cancer in its earliest - and most treatable - stages, according to a study conducted by researchers in Boston.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Alzheimer's Association commends U.S. House Representatives for new legislation

As the leading advocacy, research and support organization for Alzheimer's disease, the Alzheimer's Association commends Representatives Christopher Smith and Edward Markey for their leadership in introducing the Alzheimer's Breakthrough Act (H.R.1897) in the U.S. House of Representatives.

16 May 2011

AgenoLAB acquires Roche´s RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

13 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test.

From Quest Diagnostics 13 May 2011

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

Targeted biopsy, a major advance in prostate cancer diagnostics, was detailed by a UCLA team in the current issue of Urologic Oncology. The new technology fuses MRI with real-time 3D ultrasound, providing an exacting method to obtain biopsy specimens from suspicious areas in the prostate.

12 May 2011

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

Fluxion Biosciences announced today that the Karp Laboratory at the Brigham and Women's Hospital (BWH) has purchased the BioFlux 1000 system, which will be applied in their stem cell homing research.

From Fluxion Biosciences 12 May 2011

Response Biomedical first quarter total revenues increase 59% to $2,470,560

Response Biomedical Corporation reported financial results for the first quarter ended March 31, 2011. Total revenues for the three-month period ended March 31, 2011 increased 59% to $2,470,560 compared to $1,549,479 for the same period last year.

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Long non-coding RNA promotes melanoma cell survival and invasion

Traditionally, RNA was mostly known as the messenger molecule that carries protein-making instructions from a cell's nucleus to the cytoplasm. But scientists now estimate that approximately 97 percent of human RNA doesn't actually code for proteins at all. A flurry of research in the past decade has revealed that some types of non-coding RNAs switch genes on and off and influence protein function.

11 May 2011

FDA clears Meridian's new C. difficile immunoassay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier C. difficile GDH.

11 May 2011

Diagnostics News and Research

MDxHealth reduces first quarter net loss by 17%

Early childhood food allergies increase risk of severe allergy-related conditions and asthma later in life

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

USPTO issues notice of allowance to Vermillion's Peripheral Artery Disease biomarker patent

Celgene, Foundation Medicine partner for clinical cancer genomic testing platforms

Boston Software Systems to sponsor Revenue Cycle track of presentations at 2011 MUSE Conference

GenturaDx completes external HSV 1&2 alpha studies for IDbox System

Simple, minimal invasive technique could help detect early-stage lung cancer

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Alzheimer's Association commends U.S. House Representatives for new legislation

AgenoLAB acquires Roche´s RTCA Cardio Instrument

New study sheds light on origins of myeloid leukemia

Study: OVA1 blood test can accurately predict ovarian cancer in women with pelvic masses

Prostrate cancer patients can benefit from new MRI-ultrasound fusion

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

Response Biomedical first quarter total revenues increase 59% to $2,470,560

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Long non-coding RNA promotes melanoma cell survival and invasion

FDA clears Meridian's new C. difficile immunoassay

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News